

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



国药集团
SINOPHARM

國藥控股股份有限公司 SINOPHARM GROUP CO. LTD.*

(A joint stock limited company incorporated in the People's Republic of China with limited liability and carrying on business in Hong Kong as 國控股份有限公司)
(Stock Code: 01099)

ANNOUNCEMENT PRINCIPAL FINANCIAL DATA OF SINOPHARM ACCORD FOR THE NINE MONTHS ENDED 30 SEPTEMBER 2019

Reference is made to the overseas regulatory announcement dated 23 October 2019 (the “**Announcement**”) and issued by Sinopharm Group Co. Ltd. (the “**Company**”) in relation to the third quarterly report for the nine months ended 30 September 2019 of China National Accord Medicines Corporation Ltd. (“**Sinopharm Accord**”), a subsidiary of the Company and whose A shares and B shares are listed on the Shenzhen Stock Exchange (stock code: 000028 for A shares; 200028 for B shares).

The board of directors of the Company would like to draw the attention of its shareholders and the public investors to the following principal unaudited financial data of Sinopharm Accord for the nine months ended 30 September 2019 as set out in the Announcement.

PRINCIPAL ACCOUNTING DATA AND FINANCIAL INDICATORS OF SINOPHARM ACCORD

Unit: Yuan
Currency: RMB

	At the end of the reporting period	At the end of last year	Changes of this period-end over the end of last year	
Total assets	34,816,993,187.67	28,930,300,519.97		20.35%
Net assets attributable to shareholders of listed company	12,451,750,624.00	11,618,432,603.28		7.17%
	Current period	Changes of this period over the same period of last year	Nine months ended 30 September 2019	Changes of nine months ended 30 September 2019 over the same period of last year
Operating revenue	13,647,793,431.64	24.21%	38,875,940,809.07	22.38%
Net profit attributable to shareholders of the listed company	311,310,706.52	9.14%	962,144,066.92	3.79%
Net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses	303,365,280.52	7.45%	943,065,728.47	4.14%
Net cash flow arising from operating activities	--	--	1,072,962,161.22	90.24%
Basic earnings per share (RMB/Share)	0.735	10.36%	2.247	3.79%
Diluted earnings per share (RMB/Share)	0.735	10.36%	2.247	3.79%
Weighted average ROE	2.53%	decreased by 0.09 percentage point	7.94%	decreased by 1.27 percentage points

Note: the weighted average ROE decreased by 0.09 percentage point compared to the same period of last year, and the change from the beginning of the year to the end of the period of weighted average ROE decreased by 1.27 percentage points compare to the same period of last year, this is mainly due to that a strategy investor was introduced by Guoda Drugstore (a subsidiary of Sinopharm Accord) in the second half of last year.

This announcement is made pursuant to Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) and Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited.

By order of the Board
Sinopharm Group Co. Ltd.
Li Zhiming
Chairman

Shanghai, the PRC
23 October 2019

As at the date of this announcement, the executive directors of the Company are Mr. Li Zhiming, Mr. Yu Qingming and Mr. Liu Yong; the non-executive directors of the Company are Mr. Chen Qiyu, Mr. Ma Ping, Mr. Hu Jianwei, Mr. Deng Jindong, Mr. Wen Deyong, Ms. Guan Xiaohui and Ms. Dai Kun; and the independent non-executive directors of the Company are Mr. Yu Tze Shan Hailson, Mr. Tan Wee Seng, Mr. Liu Zhengdong, Mr. Zhuo Fumin and Mr. Chen Fangruo.

** The Company is registered as a non-Hong Kong company under the Hong Kong Companies Ordinance under its Chinese name and the English name "Sinopharm Group Co. Ltd.".*